Trinity Biotech (ADR) (TRIB)
Makes rapid HIV tests, haemoglobin systems and specialty clinical diagnostics.
$7.50
After hours+0.17 (+2.33%)
At close$7.33(−0.27%)
In millions of USD, except per-share figures
| In millions | Q1 FY23Mar 2023 | Q2 FY23Jun 2023 | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15 | 14 | 15 | 13 | 15 | 16 | 15 | 16 | 8 | 11 | 14 | 11 |
| Cost of revenue | 9 | 9 | 10 | 9 | 10 | 10 | 10 | 11 | 6 | 7 | 8 | 8 |
| Gross profit | 6 | 5 | 4 | 4 | 5 | 6 | 5 | 5 | 2 | 4 | 6 | 4 |
| 9 | 9 | 9 | 8 | 8 | 10 | 8 | 16 | 6 | 7 | 7 | 6 | |
| Research & development | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Selling, general & administrative | 9 | 8 | 8 | 6 | 7 | 6 | 7 | 8 | 5 | 7 | 6 | 5 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 7 | 0 | 0 | 0 | 0 |
| Operating income | −4 | −15 | −5 | −3 | −3 | −4 | −3 | −12 | −5 | −3 | −1 | −3 |
| −2 | −4 | −2 | −2 | 0 | −3 | −2 | −4 | −4 | −3 | −5 | −15 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | — | 0 | — | 0 |
| Interest expense | 3 | 4 | 2 | 2 | 0 | 3 | 3 | 4 | 2 | 2 | 4 | 13 |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | 2 | −1 | −1 | 0 | 0 | 0 | 0 |
| Income before tax | −6 | −19 | −6 | −6 | −3 | −7 | −5 | −16 | −9 | −6 | −5 | −18 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | — | 0 | 0 | 0 |
| Net income from continuing operations | −6 | −18 | −7 | −6 | −3 | −7 | −5 | −16 | — | −6 | −5 | −17 |
| Discontinued operations | 0 | 12 | 0 | 0 | 0 | 0 | 0 | −1 | 0 | 0 | 0 | 0 |
| Other adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | 0 | 0 | 0 |
| Net income | −6 | −6 | −7 | −6 | −3 | −7 | −5 | −17 | −9 | −6 | −5 | −17 |
| EPS, basic | −$0.83 | −$0.78 | −$0.88 | −$21.60 | −$11.16 | −$21.30 | −$13.80 | −$35.88 | −$14.46 | −$9.72 | −$8.22 | −$28.20 |
| EPS, diluted | −$0.83 | −$0.78 | −$0.88 | −$21.60 | −$11.16 | −$21.30 | −$13.80 | −$35.88 | −$14.46 | −$9.72 | −$8.22 | −$28.20 |
| Weighted average shares, basic | 8 | 8 | 8 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| Weighted average shares, diluted | 8 | 8 | 8 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| EBITDA | −3 | −14 | −4 | −3 | −2 | −4 | −1 | −10 | −4 | −2 | 0 | −2 |
| Depreciation & amortization | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 |
| EBIT | −4 | −15 | −4 | −3 | −3 | −4 | −2 | −10 | −5 | −3 | −1 | −3 |
